- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05286736
Neuroplasticidade na Doença de Parkinson
Plasticidade dos sistemas motores no estágio inicial da doença de Parkinson
The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI), from Dr. Noam Harel's protocol IRB# STUDY00008096, and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. The TMS experiment will use a Magstim Bistimn 2002 transcranial magnetic stimulation (TMS) unit and standard figure-of-eight coil (70 mm diameter) to deliver stimulation on the surface of the scalp. Stimulation will be delivered using either a single pulse or with a paired-pulse protocol (two stimuli, through the same TMS coil at inter-stimulus intervals of 50 or 80 ms). All surface EMG signals will be pre-amplified within the sensor and sent wirelessly via blue-tooth connection to a Delsys data collection system. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function will used to assess behavioral status at baseline and 30-36 months later.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adults diagnosed with Parkinson's Disease (early diagnosis, currently untreated) and age- and sex-matched healthy controls
Descrição
Inclusion Criteria:
Participants with PD
- Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
- Not receiving levodopa or dopamine agonist to treat PD (at baseline)
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
- Age- (+/- 3 years) and sex-matched to participants with PD
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters
Exclusion Criteria:
- Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
- History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
- History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
- Other significant neurological disorders that may affect participation or performance in the study
- Implanted DBS or other neurosurgeries to treat PD
- Pregnancy
Additional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions):
- History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
- Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.
- Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
- Pacemaker or any implanted device
- History of surgery on blood vessels, brain, or heart
- Unexplained, recurring headaches or concussion within the last six months
- Severe hearing impairment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Early (untreated) Parkinson's Disease
Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
|
Healthy Controls
Age- and sex-matched healthy controls. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in volume of Subthalamic Nucleus
Prazo: Baseline, 30-36 months
|
The volume of the subthalamic nucleus is assessed using MRI and reported in millimeters cubed (mm^3). |
Baseline, 30-36 months
|
|
Change in fractional Anisotropy of Subthalamic Nucleus
Prazo: Baseline, 30-36 months
|
Fractional anisotropy, measured using MRI, is a unit-less value between zero and one that describes the degree of anisotropy of water diffusion in a specified brain area. Higher values indicate a greater degree of anisotropy, while a score of zero indicates isotropic diffusion. |
Baseline, 30-36 months
|
|
Change in cortico-STN Connectivity
Prazo: Baseline, 30-36 months
|
Cortico-Subthalamic nucleus connectivity is measured using MRI and reported as a z score (unitless). |
Baseline, 30-36 months
|
|
Change in paired Associative Stimulation-Motor Evoked Potential (PAS-MEP)
Prazo: Baseline, 30-36 months
|
Motor evoked potential is measured as the amplitude of change in target muscle electrical activity following transcranial magnetic stimulation (TMS) and reported in units of millivolts (mV). |
Baseline, 30-36 months
|
|
Change in Mattis Dementia Rating Scale 2 (DRS-2)
Prazo: Baseline, 30-36 months
|
The DRS-2 consists of 24 items, rated on a scale from 0 to 6. Item scores are combined into five subscales: attention (8 items), initiation/perseveration (11 items), construction (6 items), conceptualization ( 6 items), and memory (5 items). These five subscale scores are summed to calculate a total score ranging from from 0 to 144 points, with lower scores indicating worse performance due to dementia. |
Baseline, 30-36 months
|
|
Change in Rey Complex Figure and Matrix Reasoning of the Wechsler Adult Intelligence Scale - IV
Prazo: Baseline, 30-36 months
|
Measure of visuospatial construction, memory and reasoning. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Stroop Color Word Test
Prazo: Baseline, 30-36 months
|
Measure of response inhibition, selective attention and processing. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Wisconsin Card Sorting Test
Prazo: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Subtest
Prazo: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Brief Visuospatial Memory Test - Revised (BVMT-R)
Prazo: Baseline, 30-36 months
|
Measure of non-verbal (visuospatial) learning and memory abilities. Scaled score based on age norms. |
Baseline, 30-36 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Sinucleinopatias
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Neurodegenerativas
- Distúrbios do Movimento
- Distúrbios parkinsonianos
- Doenças dos Gânglios da Base
- Doença de Parkinson
- Técnicas de investigação
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Diagnóstico imagens
- Técnicas de diagnóstico, neurológico
- Neuroimagem
Outros números de identificação do estudo
- NEUR-2019-28388
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .